“Because SPARC is designed to run well beyond Q>1, we have lots of room to maneuver as we operate the machine,” said Clayton Myers, who leads the CFS plasma diagnostics team and is slated slated to discuss our Q>1 approach at APS-DPP. “Part of the reason we’re confident SPARC will meet this early performance goal is because we have different paths to success.”